GLP-1 medications and weight loss: what the sex differences data actually shows

Yang et al. searched five major databases and analyzed 14 randomized controlled trials covering five GLP-1 receptor agonists: dulaglutide, exenatide, liraglutide, semaglutide, and retatrutide. Trials enrolled participants averaging about 92 kg at baseline; women made up between 37% and 67% of participants across studies.

The meta-analysis found women lost a mean of 1.04 kg more than men (95% CI 0.70–1.38 kg; p<0.01). Four trials that reported percentage body weight change showed women lost a mean of 1.69 percentage points more (95% CI 0.78–2.61; p<0.01).

The gap was not uniform across drugs or contexts. It was larger in:

• Trials where the average weight reduction exceeded 5% of body weight
• Trials targeting obesity indications, compared with type 2 diabetes management
• Specific drugs: semaglutide (MD 1.04 kg, 95% CI 0.45–1.63), dulaglutide (MD 0.88 kg, 95% CI 0.63–1.12), liraglutide (MD 1.30 kg, 95% CI 0.48–2.12), and retatrutide (MD 4.21 kg, 95% CI 1.75–6.67) in a Phase 2 trial
• Exenatide showed no statistically significant sex difference in weight reduction

A second systematic review by Alexander et al. (PMID 41770554, 2026) reached a consistent conclusion: GLP-1 receptor agonists produced greater weight loss among women than men, with variability across the population studied.

One important counterpoint: FDA labels for semaglutide state that the drug's efficacy is not significantly impacted by sex, age, race, ethnicity, BMI, or baseline body weight. These labels reflect FDA's own review of sex-stratified trial data. The meta-analysis and the regulatory label are not necessarily in conflict — a modest average difference can coexist with labeling that finds no clinically significant subgroup effect.

The Yang et al. paper outlines several proposed mechanisms:

Pharmacokinetics. Women tend to have lower body weight and lower GLP-1 drug clearance rates, leading to higher plasma drug concentrations at equivalent doses. The drug, in effect, acts more intensely per kilogram.

Hormonal interaction. GLP-1 and estrogen may act together to activate appetite-regulating pathways in the brain — specifically the supramammillary nucleus — amplifying appetite suppression in women.

Gastrointestinal side effects. Women experience more nausea and GI side effects from GLP-1 medications on average, which may independently reduce caloric intake and contribute to greater weight loss.

Adherence patterns. Some data suggests women may adhere more consistently to GLP-1 regimens, though this was not directly controlled in the included trials.

These are hypothesized mechanisms drawn from aggregate data — not confirmed for any individual person, and not a basis for clinical decisions about your treatment plan.

The average difference of about 1 kg is statistically real at the population level, but it is modest. Most of the well-documented benefits of GLP-1 therapy — cardiovascular protection, blood pressure reduction, glycemic control, body weight — are not sex-dependent based on current evidence.

If you are a man losing less weight than someone else on the same medication, the reason is far more likely to involve individual variation in diet, activity, starting weight, dose, duration, comorbidities, or metabolic history — not your sex.

What the research does not support: adjusting your dose because of sex-based average differences, or concluding your medication is not working because someone else's results were better.

The data suggest women may, on average, experience somewhat greater weight loss — particularly at higher doses or in obesity-targeted regimens. This does not mean any individual woman will achieve better results than her clinician has projected. Trial averages vary widely across individuals, and FDA labels reflect extensive regulatory review of sex-subgroup data.

Higher rates of gastrointestinal side effects in women are a real consideration. If nausea or other GI effects are affecting your quality of life or your ability to consistently take your medication, that conversation with your prescriber matters.

• Whether the sex gap persists at the longer treatment durations and highest doses now widely prescribed (most trials in the meta-analysis used earlier formulations and dose regimens)
• Whether sex-based differences in weight loss translate into meaningful differences in cardiovascular outcomes or other health endpoints beyond body weight
• The role of menopausal hormonal status, which was not disaggregated in most included trials — postmenopausal women may respond differently than premenopausal women
• Whether the difference is partly explained by higher GI side effects in women (greater caloric reduction from nausea and GI symptoms), or reflects a distinct pharmacological mechanism

• What weight loss timeline and magnitude is realistic for me specifically, based on my starting point, the drug I'm on, and my history?
• If my weight loss has plateaued, what should we assess next — dosing, timing, adherence factors, or a different medication?
• Are there factors in my specific situation — other medications, hormonal history, GI tolerability — that affect how well this therapy works for me?

• Monthly weight at a consistent time and conditions (same time of day, same scale)
• Appetite and food noise changes over time — these can be early signals of how well the drug is working for you
• GI side effects, particularly nausea, and whether they change with dose adjustments
• Blood pressure, fasting glucose, and lipid panel at scheduled follow-ups with your care team

Population-level averages are useful for understanding a drug. They do not determine your result.

GLP-1 medications are among the most effective anti-obesity tools currently available — for both sexes. A mean difference of about 1 kg says little about what any one person will experience over 12 or 24 months of treatment. If your results feel unexpected, the right conversation is with your prescriber — not a headline.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• Yang Y, He L, Han S, et al. Sex differences in the efficacy of glucagon-like peptide-1 receptor agonists for weight reduction: a systematic review and meta-analysis. Journal of Diabetes 2025;17(3):e70063. PMID 40040445. pmc.ncbi.nlm.nih.gov
• Alexander GC et al. Heterogeneity of treatment effects of glucagon-like peptide-1 receptor agonists for weight loss. PMID 41770554. pubmed.ncbi.nlm.nih.gov
• FDA prescribing information for Ozempic (semaglutide injection). accessdata.fda.gov